What does this research mean for the field?

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) following CAR T-cell therapy occurs in approximately 5% of patients and is associated with severe clinical manifestations, high infection risk, and significantly reduced overall survival despite intensive immunosuppression. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to analyze the incidence and outcomes of immune effector cell-associated hemophagocytic lymphohistiocytosis following CAR T-cell therapy.

May 31, 2026Open Access

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.

View Full Paper

Ask AI

Bookmark

Authors

ISInna Shaforostova MKMarie-Noelle Kronig KSKatja Seipel

Discussion

Member takes

Overview

Retrospective analysis reveals high incidence of IEC-HS in hematologic malignancy patients post CAR T-cell therapy, indicating severe outcomes.

Key Points

This study aims to analyze the incidence and outcomes of immune effector cell-associated hemophagocytic lymphohistiocytosis following CAR T-cell therapy.
Retrospective analysis of 301 patients treated with CD19- or BCMA-directed CAR T-cells from January 2019 to January 2026.
Diagnosis of IEC-HS based on American Society for Transplantation and Cellular Therapy criteria.
IEC-HS diagnosed in 14 patients (4.7%), characterized by median hyperferritinemia of 15,321 µg/L.
Mortality rate was 79% (11/14), with 1-year overall survival at 31% compared to 69% for the overall cohort (p < 0.0001).
Resolution of IEC-HS occurred in 7/14 patients, with infections noted in 11/14.

Cite This Study

Shaforostova et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd2375783ba022b6fdac8 https://doi.org/10.48620/98171

View Full Paper

Ask AI

Bookmark

May 31, 2026Open Access

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.

View Full Paper

Ask AI

Bookmark

Authors

ISInna Shaforostova MKMarie-Noelle Kronig KSKatja Seipel

Discussion

Member takes

Overview

Retrospective analysis reveals high incidence of IEC-HS in hematologic malignancy patients post CAR T-cell therapy, indicating severe outcomes.

Key Points

This study aims to analyze the incidence and outcomes of immune effector cell-associated hemophagocytic lymphohistiocytosis following CAR T-cell therapy.
Retrospective analysis of 301 patients treated with CD19- or BCMA-directed CAR T-cells from January 2019 to January 2026.
Diagnosis of IEC-HS based on American Society for Transplantation and Cellular Therapy criteria.
IEC-HS diagnosed in 14 patients (4.7%), characterized by median hyperferritinemia of 15,321 µg/L.
Mortality rate was 79% (11/14), with 1-year overall survival at 31% compared to 69% for the overall cohort (p < 0.0001).
Resolution of IEC-HS occurred in 7/14 patients, with infections noted in 11/14.

Cite This Study

Shaforostova et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd2375783ba022b6fdac8 https://doi.org/10.48620/98171

View Full Paper

Ask AI

Bookmark